메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Divamics' AI and Molecular Dynamics Platform Powers Breakthro…

SUZHOU, China, July 15, 2025 -- Divamics, a pioneer in AI-driven drug discovery, highlighted its critical role in advancing metabolic disease therapeutics through its advanced AI and molecular dynamics(MD) platform. This powerful platform recently supported the successful design of BGM1812, a novel dual AMY3R/CTR receptor agonist for obesity treatment, as published in the July 2025 issue of the Journal of Medicinal Chemistry. This achievement underscores Divamics' consistent ability to empower its partners in accelerating their drug discovery pipelines. AI-Powered Efficiency & Pre
- 김갑성 기자
- 2025-07-15 07:31
Ascletis Completes Dosing of All Participants in Its U.S. Clinical…

- The combination study, conducted in the U.S., is designed to evaluate the safety, tolerability and preliminary efficacy at Day 29 of a single-dose of ultra-long-acting subcutaneously administered ASC47 (half-life up to 40 days) in combination with four doses of semaglutide (0.5 mg, once weekly) in 28 participants with obesity. - Initiated in May 2025, all 28 participants were enrolled in less than two months. - Topline data are expected in the fourth quarter of 2025. HONG KONG, July 15, 2025 -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis&
- 김갑성 기자
- 2025-07-15 07:00
StandingTall: Revolutionise Falls Prevention Nationwide with…

SYDNEY, July 15, 2025 -- Miroma Project Factory (MPF), a leader in digital innovation for health and wellbeing, is proud to announce the expanded commercial release of StandingTall, the revolutionary home-based balance training program developed in collaboration with Professor Kim Delbaere, showcasing her life's work in falls prevention. StandingTall is a clinically validated, easy-to-use, and engaging exercise app designed to improve balance, boost confidence, and prevent falls among older adults. Now positioned for widespread adoption, StandingTall offers a proven, scalable s
- 김갑성 기자
- 2025-07-15 06:40
Concord Healthcare Announces Completion of China's Firs…

BEIJING, July 15, 2025 -- Concord Healthcare Group Co., Ltd. ("Concord Healthcare"), a subsidiary of Concord Medical Services Holdings Limited (the "Company") (NYSE: CCM), which subsidiary is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "HKSE") under the stock code 2453.HK, announced that on July 11, 2025, Guangzhou Concord Cancer Center, a subsidiary of Concord Healthcare, successfully completed the first proton therapy treatment in China for a patient with choroidal malignant melanoma. Choroidal malignant melanoma is a common
- 김갑성 기자
- 2025-07-15 04:05
Waters and BD's Biosciences & Diagnostic Solutions Busine…

Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Increases annual recurring revenue to over 70% with over 80% of revenue coming from iconic market-leading brands Anticipate approximately $345 million in annualized EBITDA synergies by 2
- 김갑성 기자
- 2025-07-14 19:00
Zepp Health Corporation to Report Second Quarter 2025 Finan…

Earnings Call Scheduled for 9:30 p.m. ET on August 3, 2025 MILPITAS, Calif., July 14, 2025 -- Zepp Health Corporation ("Zepp Health" or the "Company") (NYSE: ZEPP), a global leader in smart wearables and health technology, today announced that it will report its second quarter 2025 unaudited financial results on Sunday, August 3, 2025. Management will hold a conference call at 9:30 p.m. Eastern Time on Sunday, August 3, 2025. Listeners may access the call by dialing: US (Toll Free): +1-888-346-8982
- 김갑성 기자
- 2025-07-14 19:00
Illimis Therapeutics Closes 58 billion KRW ($42 million) Series B…

Validates technological prowess of GAIA platform and intensifies global co-development effort, including the existing partnership with Lilly Catalyze360-ExploR&D Funds to accelerate Alzheimer's and immune disease drug development, expanding GAIA-based pipeline SEOUL, South Korea, July 14, 2025 -- The Series B round saw strong participation from both existing and new investors, demonstrating high industry confidence in Illimis Therapeutics' vision and technology. Eight existing investors, including DSC Investment, Woori Venture Partners, Korea Development Bank, Aju IB
- 김갑성 기자
- 2025-07-14 15:38
Bridge Capture™ enables sensitive, scalable liquid biopsy…

Clinical study in Scientific Reports shows Bridge Capture™ detects key mutations from blood samples in metastatic colorectal cancer patients TURKU, Finland, July 14, 2025 -- Genomill Health, a biotechnology company pioneering simplified targeted library preparation for next-generation sequencing announces the results of a clinical pilot study published in Scientific Reports, demonstrating the high sensitivity of its Bridge Capture™ technology for mutation profiling in cell free DNA of metastatic colorectal cancer patients. Study shows that Bridge Capture™ matches the sensitivi
- 김갑성 기자
- 2025-07-14 15:00
Bridge Capture™, 대장암 액체 생검 파일럿 연구에서 확장 가능한 고감도 분석 기술…

사이언티픽 리포트 (Scientific Reports)에 게재된 임상 연구, Bridge Capture™로 전이성 대장암 환자의 혈액 샘플에서 주요 돌연변이 검출 투르쿠, 핀란드, 2025년 7월 14일 -- 차세대 염기서열분석을 위한 간소화된 표적 라이브러리 전처리 기술을 선도하는 생명공학 기업 지노밀 헬스(Genomill Health)가 Bridge Capture™ 기술의 높은 민감도를 입증한 임상 파일럿 연구 결과를 과학 저널 '사이언티픽 리포트(Scientific Reports)'에 발표했다. 이번 연구는 전이성 대장암 환자의 세포 유리 DNA(cell-free DNA)를 분석하여, Bridge Capture™가 미세방울 디지털 PCR(ddPCR)과 동등한 민감도로 돌연변이를 검출할 수 있음을 보여줬다. ddPCR은 해당 분야의 '골드 스탠더드'로 평가받는 기술이다. Bridge Capture™는 무제한 확장 가능한 유전자 패널, 간단하고 비용 효율적인 워크플로를 통해 분산형 NGS 검사를 가능하게 한다는 점에서 큰 주목을 받고 있다. 이 연구는 아리 리스티매키(Ari Ristimäki) 교수 그룹
- 김갑성 기자
- 2025-07-14 15:00
MGI Tech Won Green World Award for Sustainable Contribution…

AUCKERLAND, New Zealand, July 14, 2025 -- MGI Tech Co., Ltd. ("MGI"), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to announce that it has been awarded the Green World Champion in the Environmental Improvement: Conservation & Wildlife Projects sector of Green World Award 2025. This award recognizes MGI's groundbreaking efforts in utilizing genomics technology to support the conservation of Thai mangrove species. MGI's collaboration with the Thai National Omics Center aims to introduce genetic diversity in
- 김갑성 기자
- 2025-07-14 14:11

이전

91 92 93 94 95 96 97 98 99 100

많이 본 기사

최근기사

2025-10-20_MON

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 20일 12시 00분